Q4 2017 Sentiment Nektar Therapeutics (NASDAQ:NKTR)

May 17, 2018 - By Bradley Stiles

Nektar Therapeutics (NASDAQ:NKTR) Logo

Sentiment for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) institutional sentiment decreased to 1.19 in Q4 2017. Its down -0.21, from 1.4 in 2017Q3. The ratio has dropped, as 119 investment professionals increased and opened new positions, while 100 sold and trimmed equity positions in Nektar Therapeutics. The investment professionals in our partner’s database now hold: 150.36 million shares, up from 148.76 million shares in 2017Q3. Also, the number of investment professionals holding Nektar Therapeutics in their top 10 positions increased from 5 to 11 for an increase of 6. Sold All: 18 Reduced: 82 Increased: 54 New Position: 65.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $13.46 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

The stock decreased 8.46% or $7.26 during the last trading session, reaching $78.54. About 3.98 million shares traded or 36.68% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since May 17, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on August, 14. They expect $0.27 earnings per share, up 169.23 % or $0.66 from last year’s $-0.39 per share. NKTR’s profit will be $46.28M for 72.72 P/E if the $0.27 EPS becomes a reality. After $-0.60 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -145.00 % EPS growth.

Cormorant Asset Management Llc holds 12.49% of its portfolio in Nektar Therapeutics for 2.00 million shares. Camber Capital Management Llc owns 3.35 million shares or 9.79% of their US portfolio. Moreover, First Light Asset Management Llc has 5.76% invested in the company for 351,741 shares. The New York-based Duquesne Family Office Llc has invested 5.52% in the stock. Bridger Management Llc, a New York-based fund reported 1.37 million shares.

Since January 1, 0001, it had 0 insider buys, and 21 selling transactions for $88.95 million activity.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Ratings analysis reveals 100% of Nektar Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating Nektar Therapeutics, 6 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $80.0 while the high is $125. The stock’s average target of $111.33 is 41.75% above today’s ($78.54) share price. NKTR was included in 9 notes of analysts from January 9, 2018. PiperJaffray maintained the stock with “Overweight” rating in Friday, April 13 report. The firm has “Buy” rating by H.C. Wainwright given on Monday, April 2. The firm earned “Buy” rating on Monday, April 9 by Cowen & Co. The firm earned “Buy” rating on Friday, May 11 by Canaccord Genuity. The firm earned “Buy” rating on Wednesday, January 10 by Canaccord Genuity. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Mizuho on Thursday, March 29. The firm earned “Buy” rating on Friday, April 6 by Mizuho.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: “Nektar’s (NKTR) CEO Howard Robin on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018, also Seekingalpha.com with their article: “Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise” published on May 16, 2018, Nasdaq.com published: “3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies …” on May 11, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Seekingalpha.com and their article: “Merck Is Inexpensive – Cramer’s Lightning Round (5/7/18)” published on May 08, 2018 as well as Streetinsider.com‘s news article titled: “Nektar Therapeutics (NKTR) Misses Q1 EPS by 69c, Miss on Revenues” with publication date: May 10, 2018.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.